Kura Oncology (NASDAQ:KURA) Shares Down 2.7% - Should You Sell?

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) fell 2.7% on Monday . The company traded as low as $7.69 and last traded at $7.63. 44,364 shares changed hands during trading, a decline of 96% from the average session volume of 1,057,173 shares. The stock had previously closed at $7.84.

Wall Street Analyst Weigh In

KURA has been the subject of a number of research reports. Scotiabank lowered their target price on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating for the company in a research note on Wednesday, January 8th. UBS Group cut their price objective on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating on the stock in a research report on Thursday, March 6th. Cantor Fitzgerald upgraded Kura Oncology to a "strong-buy" rating in a report on Tuesday, March 4th. JMP Securities restated a "market outperform" rating and issued a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. Finally, BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.50.

Kura Oncology Trading Down 1.9 %

The company has a market cap of $565.69 million, a P/E ratio of -2.98 and a beta of 0.85. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The business has a 50 day moving average price of $7.83 and a 200-day moving average price of $12.14.

Remove Ads

Kura Oncology (NASDAQ:KURA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to the consensus estimate of $57.96 million. Analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares in the company, valued at approximately $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mollie Leoni sold 4,963 shares of the business's stock in a transaction on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the sale, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock valued at $92,307 over the last three months. Insiders own 5.50% of the company's stock.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of KURA. Virtus ETF Advisers LLC increased its position in Kura Oncology by 71.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock worth $64,000 after acquiring an additional 3,061 shares during the period. Harbor Advisors LLC bought a new position in shares of Kura Oncology during the fourth quarter worth approximately $87,000. E Fund Management Co. Ltd. acquired a new stake in shares of Kura Oncology in the fourth quarter valued at approximately $90,000. Corton Capital Inc. bought a new stake in shares of Kura Oncology in the fourth quarter valued at approximately $99,000. Finally, Optimize Financial Inc acquired a new position in Kura Oncology in the 4th quarter valued at $100,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.